Anti-Hypertensive Drugs - Eastern Africa

Eastern Africa

Highlights

The Eastern African market for Anti-Hypertensive Drugs market is anticipated to witness a significant surge in revenue, with a projected amount of US$35.50m by the year 2024.
This is expected to be followed by a steady annual growth rate of 0.40% (CAGR 2024-2029), ultimately resulting in a market volume of US$36.21m by 2029.
When compared globally, it is noteworthy that United States is expected to generate the highest revenue, amounting to US$12.29bn in 2024.
In Eastern Africa, the demand for anti-hypertensive drugs is steadily rising due to an increase in hypertension cases.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The Anti-Hypertensive Drugs market in Eastern Africa has been steadily growing in recent years.

Customer preferences: As in many other regions, customers in Eastern Africa are increasingly concerned about their health and well-being. This has led to a growing demand for anti-hypertensive drugs, which are used to treat high blood pressure. Patients are also becoming more aware of the importance of regular check-ups and are seeking medical attention earlier, which has contributed to the growth of the market.

Trends in the market: One of the key trends in the Anti-Hypertensive Drugs market in Eastern Africa is the increasing availability of generic drugs. This has made treatment more affordable for patients, particularly those who are uninsured or underinsured. Additionally, many governments in the region have implemented policies to encourage the use of generic drugs, which has further boosted their popularity.Another trend in the market is the growing use of combination therapies. These are drugs that combine two or more active ingredients, and are often more effective than single-ingredient drugs. Combination therapies are becoming increasingly popular in Eastern Africa, as they offer a convenient and cost-effective way to treat high blood pressure.

Local special circumstances: One of the key challenges facing the Anti-Hypertensive Drugs market in Eastern Africa is the lack of healthcare infrastructure in many countries in the region. This can make it difficult for patients to access treatment, particularly in rural areas. However, many governments in the region are investing in healthcare infrastructure, which is expected to improve access to treatment in the coming years.Another challenge facing the market is the high cost of imported drugs. Many countries in Eastern Africa rely on imported drugs, which can be expensive due to shipping and import costs. However, some countries in the region are beginning to develop their own pharmaceutical industries, which could help to reduce the cost of drugs in the future.

Underlying macroeconomic factors: The Anti-Hypertensive Drugs market in Eastern Africa is expected to continue growing in the coming years, driven by a number of macroeconomic factors. These include rising incomes, increasing urbanization, and growing awareness of the importance of healthcare. Additionally, many governments in the region are investing in healthcare infrastructure, which is expected to improve access to treatment and further boost demand for anti-hypertensive drugs.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.